NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings results on Thursday, February, 13th. The biotechnology company reported ($1.35) EPS for the quarter, beating the Zacks' consensus estimate of ($1.71) by $0.36. The biotechnology company had revenue of $51.53 million for the quarter, compared to analysts' expectations of $26 million. Blueprint Medicines had a negative return on equity of 72.52% and a negative net margin of 522.75%. The business's quarterly revenue was up 4888.7% on a year-over-year basis. During the same period last year, the firm earned ($1.83) earnings per share. View Blueprint Medicines' Earnings History.

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Blueprint Medicines.

12 analysts have issued 12-month target prices for Blueprint Medicines' stock. Their forecasts range from $70.00 to $125.00. On average, they expect Blueprint Medicines' stock price to reach $104.58 in the next year. This suggests a possible upside of 56.1% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

News articles about BPMC stock have trended somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Blueprint Medicines.

Some companies that are related to Blueprint Medicines include GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD) and Reata Pharmaceuticals (RETA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Nektar Therapeutics (NKTR), AbbVie (ABBV), Stratasys (SSYS), Canopy Growth (CGC), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Xilinx (XLNX) and STMicroelectronics (STM).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Westfield Capital Management Co. LP (1.57%), Eagle Asset Management Inc. (1.55%) and Perceptive Advisors LLC (1.26%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Victory Capital Management Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc. and Spark Investment Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

BPMC stock was purchased by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Jane Street Group LLC, Sectoral Asset Management Inc and Guggenheim Capital LLC. View Insider Buying and Selling for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $66.98.

Blueprint Medicines has a market capitalization of $3.62 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]